FOR IMMEDIATE RELEASE
December 8, 2020 Ann Arbor, MI
Genomenon Inc., a leading genomic health IT company, today announced that Healthcare Tech Outlook has recognized Genomenon as a Top 10 Precision Medicine Solution Provider for 2020. The honor is due to its innovations in genomic intelligence for both pharmaceutical research and clinical diagnostics.
Healthcare Tech Outlook advises healthcare decision-makers around the world, giving them critical information on adopting, innovating, and building new programs and approaches to enhance their capability to provide care. Read the article about Genomenon on HealthcareTechOutlook.com.
Genomenon’s Mastermind Genomic Search Engine is an evidence-based interpretation tool, which provides immediate insight into of millions of scientific articles and supplemental data on every disease, gene, and mutation found in the literature. Mastermind is used by hundreds of diagnostic labs around the world in the diagnosis of patients with rare diseases and cancer.
Genomenon also is a leading provider of genomic data to pharmaceutical and biopharma companies enabling them to understand diseases at a molecular level.
Researchers use Genomenon’s data for drug discovery, clinical trial stratification and companion diagnostic development – especially in the areas around rare genetic diseases and cancer.
“We’re on a mission to save and improve lives by making genomic information actionable.” said Klein. “What an honor to be recognized for the significant impact we are making in the practice of Precision Medicine.”
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
